NVO logo

NVO
Novo Nordisk A/S

26,538
Mkt Cap
$160.45B
Volume
73.15M
52W High
$112.52
52W Low
$45.05
PE Ratio
13.85
NVO Fundamentals
Price
$44.97
Prev Close
$47.63
Open
$43.43
50D MA
$53.91
Beta
0.70
Avg. Volume
12.12M
EPS (Annual)
$3.29
P/B
7.91
Rev/Employee
$551,951.47
Loading...
Loading...
News
all
press releases
Novo Nordisk A/S (NYSE:NVO) Lowered to "Hold" Rating by HSBC
HSBC reaffirmed a "hold" rating on shares of Novo Nordisk A/S in a research report on Monday...
MarketBeat·5h ago
News Placeholder
More News
News Placeholder
Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?
Biogen stock rises as Novo Nordisk's Alzheimer's trials disappoint, spotlighting Leqembi's role and a new immunology collaboration with Dayra Therapeutics.read more...
Benzinga·5h ago
News Placeholder
Holiday air travel, Novo Nordisk trial results, 'Wicked: For Good' debut and more in Morning Squawk
Here are five key things investors need to know to start the trading day...
CNBC: Technology·8h ago
News Placeholder
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.
Zacks·8h ago
News Placeholder
Stock Market Today: Futures Tip Up to Start Week; Novo Nordisk Plummets After Ozempic Alzheimer's Miss
This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here.Happy Monday. This is TheStreet's Stock...
TheStreet.com·8h ago
News Placeholder
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally
LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.
Zacks·8h ago
News Placeholder
Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market Session
read more...
Benzinga·8h ago
News Placeholder
Novo Nordisk's Blockbuster Weight-Loss Drug Flops In Alzheimer's Trial
Novo Nordisk's stock falls as semaglutide Alzheimer's trials show no significant benefit in reducing disease progression.read more...
Benzinga·9h ago
News Placeholder
Novo Nordisk Plunges After Ozempic Pill Fails Alzheimer's Trials - Shares Suffer Worst Year Ever
Novo Nordisk Plunges After Ozempic Pill Fails Alzheimer's Trials - Shares Suffer Worst Year Ever Shares of Novo Nordisk in Copenhagen plunged the most in nearly four months after top-line results...
Zero Hedge·9h ago
News Placeholder
28,257 Shares in Novo Nordisk A/S $NVO Acquired by Longfellow Investment Management Co. LLC
Longfellow Investment Management Co. LLC purchased a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the second quarter, according to its most recent filing with the Securities...
MarketBeat·9h ago

Latest NVO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.